神经肿瘤学神经功能评估(NANO)量表:一种用于整合到神经肿瘤学疗效评估(RANO)标准中的神经功能评估工具
由国际多学科专家起草的NANO量表,基于常规门诊检查对9个神经功能域进行客观量化评估并定义总体缓解标准。一项前瞻性跨国研究显示观察者间一致率超过90%,kappa统计量为0.35至0.83,中位评估时间为4分钟。该量表设计用于与影像学评估结合,在临床试验和日常实践中对神经肿瘤患者进行总体疗效评估。
要点
- NANO量表基于常规门诊观察和测试,量化评估9个相关神经功能域。
- 前瞻性跨国研究显示观察者间一致率超过90%,kappa统计量为0.35至0.83。
- 中位评估时间为4分钟(四分位距3至5分钟)。
核心结论
- NANO量表提供了一种客观的临床医生报告的神经功能结局指标,观察者间一致率高。
- 该量表设计用于与影像学评估结合,在临床试验和日常实践中为神经肿瘤患者提供总体疗效评估。
- 该量表补充现有患者报告结局和认知测试,共同构成脑肿瘤患者健康状况的全局临床结局评估。
研究设计与样本
- 由包括神经科医生、肿瘤内科医生、放射肿瘤科医生和神经外科医生在内的国际多学科专家组起草NANO量表。
- 随后在一项多中心研究中检验该量表的总体信度、观察者间变异性和可行性。
- 一项前瞻性跨国研究报告了观察者间一致率和评估时间。
主要发现
- NANO量表基于常规门诊访视中进行的直接观察和测试,对9个相关神经功能域进行可量化评估。
- 该评分定义了总体缓解标准。
- 前瞻性跨国研究显示观察者间一致率超过90%,kappa统计量为0.35至0.83(一般至几乎完全一致)。
- 中位评估时间为4分钟(四分位距3至5分钟)。
关键数值与推荐
- NANO量表评估9个相关神经功能域。
- 观察者间一致率超过90%,kappa统计量为0.35至0.83。
- 中位评估时间为4分钟(四分位距3至5分钟)。
临床怎么用
- NANO量表设计用于与影像学评估结合,在临床试验和日常实践中为神经肿瘤患者提供总体疗效评估。
- 该量表补充现有患者报告结局和认知测试,共同构成脑肿瘤患者健康状况的全局临床结局评估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Macdonald criteria and the Response Assessment in Neuro-Oncology (RANO) criteria define radiologic parameters to classify therapeutic outcome among patients with malignant glioma and specify that clinical status must be incorporated and prioritized for overall assessment. But neither provides specific parameters to do so. We hypothesized that a standardized metric to measure neurologic function will permit more effective overall response assessment in neuro-oncology. METHODS: An international group of physicians including neurologists, medical oncologists, radiation oncologists, and neurosurgeons with expertise in neuro-oncology drafted the Neurologic Assessment in Neuro-Oncology (NANO) scale as an objective and quantifiable metric of neurologic function evaluable during a routine office examination. The scale was subsequently tested in a multicenter study to determine its overall reliability, inter-observer variability, and feasibility. RESULTS: The NANO scale is a quantifiable evaluation of 9 relevant neurologic domains based on direct observation and testing conducted during routine office visits. The score defines overall response criteria. A prospective, multinational study noted a >90% inter-observer agreement rate with kappa statistic ranging from 0.35 to 0.83 (fair to almost perfect agreement), and a median assessment time of 4 minutes (interquartile range, 3-5). CONCLUSION: The NANO scale provides an objective clinician-reported outcome of neurologic function with high inter-observer agreement. It is designed to combine with radiographic assessment to provide an overall assessment of outcome for neuro-oncology patients in clinical trials and in daily practice. Furthermore, it complements existing patient-reported outcomes and cognition testing to combine for a global clinical outcome assessment of well-being among brain tumor patients.
引用
- Nayak L, DeAngelis LM, Brandes AA, et al. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017. PMID: 28453751. doi:10.1093/neuonc/nox029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。